New combo therapy targets hard-to-treat cancers
Disease control
Recruiting now
This study tests a new drug called FL115 combined with an immunotherapy (PD-1 blocker) in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 130 adults w…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Forlong Biotechnology Co., Ltd • Aim: Disease control
Last updated May 14, 2026 12:06 UTC